checkAd

     110  0 Kommentare OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting

    Regulatory News:

    OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces the procedures for participating to the Combined General Meeting, to be held on June 24, 2021 at 2:30 p.m. CET.

    As indicated in the press release dated May 19, 2021, the Combined General Meeting of June 24, 2021, will be held by live webcast, without the physical presence of shareholders or other persons usually eligible to attend pursuant to the provisions of the the order published on 25 March 2020 extended and amended by order no. 2020-1497 of 2 December 2020, decree no. 2020-418 of 10 April 2020 extended and amended by decree no. 2020-1614 of 18 December 2020 and decree no. 2021-255 of 9 March 2021.

    The prior notice to the General Meeting including the agenda, the resolutions submitted for approval and the main methods of participation and voting, and also serving as notice of the meeting, was published on May 19, 2021 in the French bulletin of mandatory legal announcements (BALO).

    • Login information

    The General Meeting will be webcast live (in French) via a web conferencing system and shareholders of OSE Immunotherapeutics are invited to login through the link:

    https://channel.royalcast.com/landingpage/oseimmunotherapeutics/202106 ...

    This link allows shareholders to register for the General Meeting as of today (and until June 24, 2021 at 2:00 p.m. CET) by entering their email address. Registrants will receive a registration confirmation in addition to the ability to add the event to their calendar.

    On June 24, 2021, shareholders will be able to connect via this same link starting at 2:00 p.m. CET. The General Meeting will start at 2:30 p.m. and attendees will be able to follow the presentation by OSE Immunotherapeutics’ management on their screen.

    Due to the closed session and in accordance with the regulations in force, it is not possible for shareholders to amend resolutions or to propose new resolutions at the General Meeting. The shareholders retain their right to ask written questions before the General Meeting. Shareholders are invited to send their questions from today and at the latest until June 22, 2021, at 12:00 to the email address: ag2021@ose-immuno.com. A common answer can be provided to these questions as long as they present the same content. Answers to written questions will be published directly on the Company's website in the section devoted to the General Meeting / “questions and answers” ​​and will then be deemed to have been given.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces the procedures for participating to the Combined General Meeting, to be held on June 24, 2021 at 2:30 p.m. CET. As indicated in the press release dated …